Human Drug Discrimination: Methodological Considerations and Application to Elucidating the Neuropharmacology of Amphetamines

Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies

Volumn , Issue , 2011, Pages 431-461

  Rush, Craig R ^a,b   Vansickel, Andrea R ^a,b   Stoops, William W ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Amphetamine neuropharmacology; Human drug discrimination; Putative pharmacotherapy efficacy

Indexed keywords

EID: 84881548345     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118023150.ch14     Document Type: Chapter

References (110)

1. Glennon, R.A., Järbe, T.U.C., Frankenheim, J. ( 1991 ). Drug discrimination: applications to drug abuse research . NIDA Research Monograph, 116.
2. Holtzman, S.G., Locke, K.W. ( 1988 ). Neural mechanisms of drug stimuli: experimental approaches. In: F.C. Colpaert, R.L. Balster, Eds. Transduction Mechanisms of Drug Stimuli. Springer - Verlag, Berlin, pp 138-153.
3. Preston, K.L., Bigelow, G.E. ( 1991 ). Subjective and discriminative effects of drugs. Behavioural Pharmacology, 2, 293-313.
4. Schuster, C.R., Johanson, C.E. ( 1988 ). Relationship between the discriminative stimulus properties and subjective effects of drugs. In: F.C. Colpaert, R.L. Balster, Eds. Transduction Mechanisms of Drug Stimuli. Springer - Verlag, Berlin, pp 161-175.
5. Schuster, C.R., Fischman, M.W., Johanson, C.E. ( 1981 ). Internal stimulus control and the subjective effects of drugs. In: C.E. Johanson, T. Thompson, Eds. Behavioral Pharmacology of Human Drug Dependence. Research Monograph 37. National Institute on Drug Abuse. Public Health Service: Alcohol, Drug Abuse, and Mental Health Administration. U.S. Department of Health and Human Services, Rockville, MD, pp 116-129.
6. Kamien, J.B., Bickel, W.K., Hughes, J.R., Higgins, S.T., Smith, B.J. ( 1993 ). Drug discrimination by humans compared to nonhumans: current status and future directions. Psychopharmacology (Berl), 111, 259-270.
7. Kelly, T.H., Stoops, W.W., Perry, A.S., Prendergast, M.A., Rush, C.R. ( 2003 ). Clinical neuropharmacology of drugs of abuse: a comparison of drug discrimination and subject - report measures. Behavioral and Cognitive Neuroscience Reviews, 2, 227-260.
8. Sevak , R.J., Stoops, W.W., Hays, L.R., Rush, C.R. ( 2009a ). Discriminative - stimulus and subject - rated effects of methamphetamine, d - amphetamine, methylphenidate and triazolam in methamphetamine - trained humans. Journal of Pharmacology and Experimental Therapeutics, 328, 1007-1018.
9. Hobbs, W.R., Rall, T.W., Verdoorn, T.A. ( 1996 ). Hypnotics and sedatives; ethanol. In: J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Gilman, Eds. Goodman's and Gilman's: The Pharmacological Basis of Therapeutics, Ninth Edition. McGraw - Hill, New York, pp 361-398.
10. Chait, L.D., Uhlenhuth, E.H., Johanson, C.E. ( 1986a ). The discriminative stimulus and subjective effects of phenylpropanolamine, mazindol and d - amphetamine in humans. Pharmacology Biochemistry and Behavior, 24, 1665-1672.
11. Lile, J.A., Stoops, W.W., Durell, T.M., Glaser, P.E.A., Rush, C.R. ( 2006 ). Discriminative - stimulus, self - reported, performance, and cardiovascular effects of atomoxetine in methylphenidate - trained humans. Experimental and Clinical Psychopharmacology, 14, 136-147.
12. Oliveto, A.H., McCance-Katz, E., Singha, A., Hameedi, F., Kosten, T.R. ( 1998 ). Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure. Behavioural Pharmacology, 9, 207-217.
13. Rush, C.R., Kollins, S.H., Pazzaglia, P.J. ( 1998 ). Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion and triazolam in d-amphetamine-trained humans. Experimental and Clinical Psychopharmacology, 6, 32-44.
14. Schuh, K.J., Schubiner, H., Johanson, C.E. ( 2000 ). Discrimination of intranasal cocaine. Behavioural Pharmacology, 11, 511-515.
15. Foltin, R.W., Fischman, M.W. ( 1988 ). Ethanol and cocaine interactions in humans: cardiovascular consequences. Pharmacology Biochemistry and Behavior, 31, 877-883.
16. Higgins, S.T., Bickel, W.K., Hughes, J.R., Lynn, M., Capeless, M.A., Fenwick, J.W. ( 1990 ). Effects of intranasal cocaine on human learning, performance and physiology. Psychopharmacology, 10, 451-458.
17. Higgins, S.T., Rush, C.R., Bickel, W.K., Hughes, J.R., Lynn, M., Capeless, M.A. ( 1993 ). Acute behavioral and cardiac effects of cocaine and alcohol combinations in humans. Psychopharmacology (Berl), 111, 285-294.
18. Chait, L.D., Evans, S.M., Grant, K.A., Kamien, J.B., Johanson, C.E., Schuster, C.R. ( 1988 ). Discriminative stimulus and subjective effects of smoked marijuana in humans. Psychopharmacology (Berl), 94, 206-212.
19. Kelly, T.H., Emurian, C.S., Baseheart, B.J., Martin, C.A. ( 1997 ). Discriminative stimulus effects of alcohol in humans. Drug and Alcohol Dependence, 48, 199-207.
20. Oliveto, A.H., Rosen, M.I., Woods, S.W., Kosten, T.R. ( 1995 ). Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans. Journal of Pharmacology and Experimental Therapeutics, 272, 231-241.
21. Chait, L.D., Uhlenhuth, E.H., Johanson, C.E. ( 1984 ). An experimental paradigm for studying the discriminative stimulus properties of drugs in humans. Psychopharmacology (Berl), 82, 272-274.
22. Chait, L.D., Uhlenhuth, E.H., Johanson, C.E. ( 1985 ). The discriminative stimulus and subjective effects of d-amphetamine in humans. Psychopharmacology (Berl), 86, 307-312.
23. Chait, L.D., Uhlenhuth., E.H., Johanson, C.E. ( 1986b ). The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfl uramine in humans. Psychopharmacology (Berl), 89, 301-306.
24. Lile, J.A., Stoops, W.W., Vansickel, A.R., Glaser, P.E.A., Hays, L.R., Rush, C.R. ( 2005a ). Aripiprazole attenuates the discriminative-stimulus effects of d-amphetamine in humans. Neuropsychopharmacology, 30, 2103-2114.
25. Lile, J.A., Stoops, W.W., Wagner, F.P., Glaser, P.E.A., Rush, C.R. ( 2005b ). Oxazepam does not modulate the behavioral effects of d-amphetamine in humans. Pharmacology Biochemistry and Behavior, 82, 270-279.
26. Rush, C.R., Stoops, W.W., Hays, L.R., Glaser, P.E.A., Hays, L.S. ( 2003 ). Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. Journal of Pharmacology and Experimental Therapeutics, 306, 195-204.
27. Rush, C.R., Stoops, W.W., Wagner, F.P., Hays, L.R., Glaser, P.E.A. ( 2004 ). Alprazolam attenuates the behavioral effects of d-amphetamine in humans. Journal of Clinical Psychopharmacology, 24, 410-420.
28. Stoops, W.W., Lile, J.A., Glaser, P.E.A., Rush, C.R. ( 2006 ). A low dose of aripiprazole attenuates the subjective effects of d-amphetamine. Drug and Alcohol Dependence, 84, 206-209.
29. Terry, P., Witkin, J.M., Katz, J.L. ( 1994 ). Pharmacological characterization of the novel discriminative stimulus effects of a low dose of cocaine. Journal of Pharmacology and Experimental Therapeutics, 270: 1041-1048.
30. Jones, H.E., Bigelow, G.E., Preston, K.L. ( 1999 ). Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure. Journal of Pharmacology and Experimental Therapeutics, 289, 1350-1361.
31. Kollins, S.H., Rush, C.R. ( 1999 ). Effects of training dose on the relationship between discriminative-stimulus and self-reported drug effects of d-amphetamine in humans. Pharmacology Biochemistry and Behavior, 64, 319-326.
32. Perkins, K.A., D'Amico, D., Sanders, M., Grobe, J.E., Wilson, A., Stiller, R.L. ( 1996 ). Infl uence of training dose on nicotine discrimination in humans. Psychopharmacology (Berl), 126, 132-139.
33. Perkins, K.A., Fonte, C., Sanders, M., White, W., Wilson, A. ( 1999 ). Effects of training dose and two-versus three-choice testing procedure on nicotine discrimination responding in humans. Psychopharmacology (Berl), 145, 418-425.
34. Rush, C.R., Critchfield, T.S., Troisi, J.R., Griffiths, R.R. ( 1995 ). Discriminative stimulus effects of diazepam and buspirone in normal volunteers. Journal of the Experimental Analysis of Behavior, 63, 277-294.
35. Broadbent, J.J., Michael, E.K., Riddle, E.E., Apple, J.B. ( 1991 ). Involvement of dopamine uptake in the discriminative stimulus effects of cocaine. Behavioural Pharmacology, 2, 187-197.
36. Cunningham, K.A., Callahan, P.M. ( 1991 ). Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology, 104, 177-180.
37. Hart, C.L., Haney, M., Foltin, R.W., Fischman, M.W. ( 2002 ). Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology (Berl), 164, 376-384.
38. Stoops, W.W., Lile, J.A., Glaser, P.E.A., Rush, C.R. ( 2005 ). Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. Experimental and Clinical Psychopharmacology, 13, 56-64.
39. Czoty, P.W., Ramanathan, C.R., Mutschler, N.H., Makriyannis, A., Bergman, J. ( 2004 ). Drug discrimination in methamphetamine-trained monkeys: effects of monoamine transporter inhibitors. Journal of Pharmacology and Experimental Therapeutics, 311, 720-727.
40. Gatch, M.B., Taylor, C.M., Flores, E., Selvig, M., Forster, M.J. ( 2006 ). Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behavioural Pharmacology, 17, 151-159.
41. Munzar, P., Laufert, M.D., Kutkat, S.W., Novakova, J., Goldberg, S.R. ( 1999 ). Effects of various serotonin agonists, antagonists, and uptake inhibitors on the discriminative stimulus effects of methamphetamine in rats. Journal of Pharmacology and Experimental Therapeutics, 291, 239-250.
42. Powell, K.R., Holtzman, S.G. ( 2000 ). Modulation of the discriminative stimulus effects of d-amphetamine by mu and kappa opioids in squirrel monkeys. Pharmacology Biochemistry and Behavior, 65, 43-51.
43. Bickel, W.K., Oliveto, A.H., Kamien, J.B., Higgins, S.T., Hughes, J.R. ( 1993 ). A novel-response procedure enhances the selectivity and sensitivity of a triazolam discrimination in humans. Journal of Pharmacology and Experimental Therapeutics, 264, 360-367.
44. Preston, K.L., Bigelow, G.E. ( 2000 ). Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. Journal of Pharmacology and Experimental Therapeutics, 295, 114-124.
45. Preston, K.L., Liebson, I.A., Bigelow, G.E. ( 1992 ). Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination. Journal of Pharmacology and Experimental Therapeutics, 261, 62-71.
46. Reisine, T., Pasternak, G. ( 1996 ). Opioid analgesics and antagonists. In: J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Gilman. Eds. Goodman's and Gilman's: The Pharmacological Basis of Therapeutics, Ninth Edition. McGraw-Hill, New York, pp 521-555.
47. Johanson, C.E., Lundahl, L.H., Schubiner, H. ( 2007 ). Effects of oral cocaine on intravenous cocaine discrimination in humans. Experimental and Clinical Psychopharmacology, 15, 219-227.
48. Rush, C.R., Baker, R.W. ( 2001 ). Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Experimental and Clinical Psychopharmacology, 9, 59-73.
49. Johanson, C.E. ( 1991a ). Discriminative stimulus effects of diazepam in humans. Journal of Pharmacology and Experimental Therapeutics, 257, 634-643.
50. Johanson, C.E. ( 1991b ). Further studies on the discriminative stimulus effects of diazepam in humans. Behavioural Pharmacology, 2, 357-367.
51. Johanson, C.E., Lundahl, L.H., Lockhart, N., Schubiner, H. ( 2006 ). Intravenous cocaine discrimination in humans. Experimental and Clinical Psychopharmacology, 14, 99-108.
52. Preston, K.L., Bigelow, G.E., Liebson, I.A. ( 1990 ). Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacology Biochemistry and Behavior, 37, 511-522.
53. Chait, L.D., Uhlenhuth, E.H., Johanson, C.E. ( 1989 ). Individual differences in the discriminative stimulus effects of d-amphetamine in humans. Drug Development Research, 16, 451-460.
54. Singha, A.K., McCance-Katz, E.F., Heck, S.A., Kosten, T.R., Oliveto, A. ( 1999 ). Individual differences in humans responding under a cocaine discrimination procedure: discriminators versus nondiscriminators. Experimental and Clinical Psychopharmacology, 7, 391-398.
55. Vansickel, A.R., Lile, J.A., Stoops, W.W., Rush, C.R. ( 2007 ). Similar discriminative-stimulus effects of D-amphetamine in women and men. Pharmacology Biochemistry and Behavior, 87, 289-296.
56. Brecht, M., O'Brien, A., von Mayrhause,r C., Anglin, M.D. ( 2004 ). Methamphetamine use behaviors and gender differences. Addictive Behaviors, 29, 89-106.
57. Westermeyer, J., Boedicker, A.E. ( 2000 ). Course, severity, and treatment of substance abuse among women versus men. American Journal of Drug and Alcohol Abuse, 26, 523-535.
58. Vansickel, A.R., Hays, L.R., Rush, C.R. ( 2006 ). Discriminative-stimulus effects of triazolam in women and men. American Journal of Drug and Alcohol Abuse, 32, 329-349.
59. Fleckenstein, A.E., Gibb, J.W., Hanson, G.R. ( 2000 ). Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. European Journal of Pharmacology, 406, 1-13.
60. Johanson, C.E., Fischman, M.W. ( 1989 ). The pharmacology of cocaine related to its abuse. Pharmacological Reviews, 41, 3-52.
61. Rothman, R.B., Glowa, J.R. ( 1995 ). A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development: focus on GBR 12909. Molecular Neurobiology, 11, 1-19.
62. Seiden, L.S., Sabol, K.E., Ricaurte, G.A. ( 1993 ). Amphetamine: effects on catecholamine systems and behavior. Annual Review of Pharmacology and Toxicology, 33, 639-677.
63. Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I., Partilla, J.S. ( 2001 ). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 39, 32-41.
64. Tidey, J.W., Bergman, J. ( 1998 ). Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. Journal of Pharmacology and Experimental Therapeutics, 285, 1163-1174.
65. Brauer, L.H., Goudie, A.J., de Wit, H. ( 1997 ). Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology (Berl), 130, 2-13.
66. Brauer, L.H., de Wit, H. ( 1995 ). Role of dopamine in d-amphetamine-induced euphoria in normal, healthy volunteers. Experimental and Clinical Psychopharmacology, 3, 371-381.
67. Brauer, L.H., de Wit, H. ( 1996 ). Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biological Psychiatry, 39, 26-32.
68. Brauer, L.H., de Wit, H. ( 1997 ). High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacology Biochemistry and Behavior, 56, 265-272.
69. Wachtel, S., Ortengren, A., de Wit, H. ( 2002 ). The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug and Alcohol Dependence, 68, 23-33.
70. Stoops, W.W., Glaser, P.E.A., Rush, C.R. ( 2011c ). Discriminative-stimulus effects of d-amphetamine following pretreatment with fl uphenazine. Unpublished data
71. Newton, T.F., Reid, M.S., De La Garza, R., Mahoney, J.J., Abad, A., Condos, R., Palamar, J., Halkitis, P.N., Mojisak, J., Anderson, A., Li S.H., Elkashef, A. ( 2008 ). Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. International Journal of Neuropsychopharmacology, 11, 1037-1045.
72. Sevak, R.J., Vansickel, A.R., Stoops, W.W., Glaser, P.E.A, Hays, L.R., Rush, C.R. ( 2011 ). Discriminative-stimulus, subject-rated and physiological effects of methamphetamine in humans pretreated with aripiprazole. Journal of Clinical Psychopharmacology, under review.
73. Weiss, F., Markou, A., Lorang, M.T., Koob, G.F. ( 1992 ). Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Research, 593, 314-318.
74. Burris, K.D., Molski, T.F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F.D., Molinoff, P.B. ( 2002 ). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D 2 receptors. Journal of Pharmacology and Experimental Therapeutics, 302, 381-389.
75. Kita, H., Kitai, S.T. ( 1988 ). Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations. Brain Research, 44, 346-352.
76. Churchill, L., Dilts, R.P., Kalivas, P.W. ( 1992 ). Autoradiographic localization of gamma-aminobutyric acidA receptors within the ventral tegmental area. Neurochemistry Research, 17, 101-106.
77. Kalivas, P.W., Duffy, P., Eberhardt, H. ( 1990 ). Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. Journal of Pharmacology and Experimental Therapeutics, 253, 858-866.
78. Finlay, J.M., Damsma, G., Fibiger, H.C. ( 1992 ). Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration. Psychopharmacology (Berl), 106, 202-208.
79. Invernizzi, R., Pozzi, L., Samanin, R. ( 1991 ). Release of dopamine is reduced by diazepam more in the nucleus accumbens than in the caudate nucleus of conscious rats. Neuropharmacology, 30, 575-578
80. Zetterstrom, T, Fillenz, M. ( 1990 ). Local administration of fl urazepam has different effects on dopamine release in striatum and nucleus accumbens: A microdialysis study. Neuropharmacology, 29, 129-134.
81. Dewey, S.L., Chaurasia, C.S., Chen, C.E., Volkow, N.D., Clarkson, F.A., Porter, S.P., Straughter-Moore, R.M., Alexoff, D.L., Tedeschi, D., Russo, N.B., Fowler, J.S., Brodie, J.D. ( 1997 ). GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse, 25, 393-398.
82. Morgan, A.E., Dewey, S.L. ( 1998 ). Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine. Synapse, 28, 60-65.
83. Druhan, J.P., Fibiger, H.C., Phillips, A.G. ( 1991 ). Infl uence of some drugs of abuse on the discriminative stimulus properties of amphetmaine. Behavioural Pharmacology, 2, 391-403
84. Mintzer, M.Z., Griffiths, R.R. ( 2003 ). Triazolam-amphetamine interaction: dissociation of effects on memory versus arousal. Journal of Psychopharmacology, 17, 17-29.
85. Preston, K.L., Bigelow, G.E. ( 1993 ). Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. Journal of Pharmacology and Experimental Therapeutics, 264, 813-823.
86. Walsh, S.L., Strain, E.C., Abreu, M.E., Bigelow, G.E. ( 2001 ). Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl), 157, 151-162.
87. Substance Abuse and Mental Health Services Administration ( 2007 ). Results from the 2006 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD.
88. National Drug Intelligence Center [NDIC] ( 2006 ). National Methamphetamine Threat Assessment 2007. U.S. Department of Justice, Washington, DC. http://www.usdoj.gov/ndic/pubs21/21821/index.htm Accessed 21 September 2009.
89. Elkashef, A., Vocci, F., Hanson, G., White, J., Wickes, W., Tiihonen, J. ( 2008a ). Pharmacotherapy of methamphetamine addiction: An update. Substance Abuse, 29, 31-49.
90. Rush, C.R., Vansickel, A.R., Lile, J.A., and Stoops, W.W. ( 2009 ). Evidence-based treatment of amphetamine dependence: Pharmacological and behavioral approaches. In: L. Cohen, F.L. Collins, A.M. Young, D.E. McChargue. and T.R. Leffingwell (Eds.). The Pharmacology and Treatment of Substance Abuse Using Evidence and Outcomes Based Perspectives. Lawrence Erlbaum Associates: Mahwah, NJ. pp. 335-358.
91. Cornish, J.W., Metzger, D., Woody, G.E., Wilson, D., McLellan, A.T., Vandergrift, B., O'Brien, C.P. ( 1997 ). Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment, 14, 529-534.
92. Rea, F., Bell, J.R., Young, M.R., Mattick, R.P. ( 2004 ). A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug and Alcohol Dependence, 75, 79-88.
93. Rose, J.E., Behm, F.M. ( 2004 ). Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine and Tobacco Research, 6, 523-532.
94. Meredith, C.W., Jaffe, C., Yanasak, E., Cherrier, M., Saxon, A.J. ( 2007 ). An open-label pilot study of risperidone in the treatment of methamphetamine dependence. Journal of Psychoactive Drugs, 39, 167-172
95. Grant, S, Fitton, A. ( 1994 ). Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs, 48, 253-273.
96. Tiihonen, J., Kuoppasalmi, K., Fohr, J., Tuomola, P., Kuikanmaki, O., Vorma, H., Sokero, P., Haukka, J., Meririnne, E. ( 2007 ). A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. American Journal of Psychiatry, 164, 160-162.
97. Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L.X., Sibley, D.R., Roth, B.L., Mailman, R. ( 2003 ). Aripiprazole, a novel antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28, 1400-1411
98. Lile, J.A., Stoops, W.W., Glaser, P.E.A., Hays, L.R., Rush, C.R. ( 2010 ). The discriminative-stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. Journal of Psychopharmacology, in press.
99. Silagy, C., Lancaster, T., Stead, L., Mant, D., Fowler, G. ( 2004 ). Nicotine replacement therapy for smoking cessation. Cochrane Database Systematic Reviews, CD000146.
100. Sofuoglu, M., Kosten, T.R. ( 2004 ). Pharmacologic management of relapse prevention in addictive disorders. Psychiatric Clinics of North America, 27, 627-648.
101. Li, S., Campbell, B.L., Katz, J.L. ( 2006 ). Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. Journal of Pharmacology and Experimental Therapeutics, 317, 1088-1096.
102. Vansickel, A.R., Stoops, W.W., Glaser, P.E.A., Rush, C.R. ( 2011a ). Discriminative-stimulus effects of methamphetamine following pretreatment with d-amphetamine. Unpublished data.
103. McBride, A.J., Sullivan, G., Blewett, A.E., Morgan, S. ( 1997 ). Amphetamine prescribing as a harm reduction measure: a preliminary study. Addiction Research, 5, 95-112.
104. Klee, H., Wright, S., Carnwath, T., Merrill, J. ( 2001 ). The role of substitute therapy in the treatment of problem amphetamine use. Drug and Alcohol Review, 20, 417-429.
105. Shearer, J., Wodak, A., Mattick R.P., Van Beek, I., Lewis, J., Hall, W., Dolan, K. ( 2001 ). Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction, 96, 1289-1296
106. Shearer, J, Sherman, J., Wodak, A., van Beek, I. ( 2002 ). Substitution therapy for amphetamine users. Drug and Alcohol Review, 21, 179-185.
107. Bredeloux, P., Dubuc, I., Costentin, J. ( 2007 ). Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. British Journal of Pharmacology, 150, 711-719.
108. Vansickel, A.R., Stoops, W.W., Glaser, P.E.A., Rush, C.R. ( 2011b ). Discriminative-stimulus effects of methamphetamine following pretreatment with bupropion. Unpublished data.
109. Elkashef, A.M., Rawson, R.A., Anderson, A.L., Li, S.H., Holmes, T., Smith, E.V., Chiang, N., Kahn, R., Vocci, F., Ling, W., Pearce, V.J., McCann, M., Campbell, J., Gorodetzky, C., Haning, W., Carlton, B., Mawhinney, J., Weis, D. ( 2008b ). Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology, 33, 1162-1170.
110. Shoptaw, S., Heinzerling, K.G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A.N., De La Garza, R., Newton, T., Ling, W. ( 2008 ). Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 96, 222-232.